Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | HTT | P42858 | 5/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18497873 | 0.90 | KDM4E (0.46) | KDM4EHTTPKMKMT2AGAA | |
| SCHEMBL18515970 | 0.89 | KDM4E (0.42) | KDM4EHTTPKMKMT2AGAA | |
| SCHEMBL29912575 | 0.89 | KDM4E (0.42) | KDM4EHTTPKMKMT2AGAA | |
| SCHEMBL20908523 | 0.82 | KDM4E (0.44) | KDM4EHTTPKMKMT2AGAA | |
| SCHEMBL18497909 | 0.79 | KDM4E (0.67) | KDM4EHTTPKMKMT2AGAA | |
| SCHEMBL3819661 | 0.77 | MAPT (0.58) | KDM4EHTTKMT2AGAAALDH1A1 | |
| SCHEMBL20838476 | 0.72 | CCR1 (0.38) | KDM4EHTTPKMKMT2AGAA | |
| SCHEMBL18515925 | 0.70 | KDM4E (0.58) | KDM4EHTTPKMKMT2AGAA | |
| SCHEMBL29912454 | 0.70 | KDM4E (0.58) | KDM4EHTTPKMKMT2AGAA | |
| SCHEMBL18497910 | 0.70 | KDM4E (0.69) | KDM4EHTTPKMKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024468-A1 | 8-HYDROXYQUINOLINE DERIVATIVES AS DIAGNOSTIC AND THERAPEUTIC AGENTS | THE GENERAL HOSPITAL CORPORATION | 2021-01-28 | — | — | US | disclosed |
| US-10781178-B2 | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-22 | — | — | US | disclosed |
| US-20180327362-A1 | 8-HYDROXYQUINOLINE DERIVATIVES AS DIAGNOSTIC AND THERAPEUTIC AGENTS | THE GENERAL HOSPITAL CORPORATION | 2018-11-15 | — | — | US | disclosed |
| WO-2017027064-A1 | 8-HYDROXYQUINOLINE DERIVATIVES AS DIAGNOSTIC AND THERAPEUTIC AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024468-A1 | 8-HYDROXYQUINOLINE DERIVATIVES AS DIAGNOSTIC AND THERAPEUTIC AGENTS | KLK3, COQ8A, PARK7 | KDM4E 2935/4885HTT 11/4885PKM 1204/4885 |
| US-20180327362-A1 | 8-HYDROXYQUINOLINE DERIVATIVES AS DIAGNOSTIC AND THERAPEUTIC AGENTS | KLK3, COQ8A, PARK7 | KDM4E 2935/4885HTT 11/4885PKM 1204/4885 |
| US-10781178-B2 | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents | KLK3, COQ8A, PARK7 | KDM4E 2935/4885HTT 11/4885PKM 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.